A Cancer Drug with Fan Mail

Copyright (c)2000 by the American Society for Clinical Investigation The crystal structure of AMP-PNP bound to Lck was used to make a model of the Abl kinase domain. Left, the general architecture of the Abl kinase domain; top right, topology of the ATP-binding cleft of the Abl protein kinase; bottom right, amino acid side chains lining the APT-binding cleft. "I feel so good that sometimes I forget I have leukemia," writes Gay Bratton of her experience with STI571, Novartis Pharma's experimenta

Tom Hollon
May 14, 2000

Copyright (c)2000 by the American Society for Clinical Investigation

The crystal structure of AMP-PNP bound to Lck was used to make a model of the Abl kinase domain. Left, the general architecture of the Abl kinase domain; top right, topology of the ATP-binding cleft of the Abl protein kinase; bottom right, amino acid side chains lining the APT-binding cleft.
"I feel so good that sometimes I forget I have leukemia," writes Gay Bratton of her experience with STI571, Novartis Pharma's experimental drug for treatment of chronic myelogenous leukemia (CML). Bratton, a high school math teacher and grandmother, started taking STI571 at Houston's M.D. Anderson Cancer Center last December as a participant in a Phase I trial of the drug. With STI571, her white blood cell counts are under control and her anemia is gone, giving her the energy to function normally.

Judy Orem was the ninth person to take STI571...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?